Brown Brothers Harriman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $50.2K | Buy |
154
+127
| +470% | +$41.4K | ﹤0.01% | 938 |
|
|
2025
Q1 | $7.29K | Sell |
27
-3
| -10% | -$810 | ﹤0.01% | 1108 |
|
|
2024
Q4 | $7.06K | Sell |
30
-22
| -42% | -$5.18K | ﹤0.01% | 1179 |
|
|
2024
Q3 | $14.3K | Buy |
52
+25
| +93% | +$6.88K | ﹤0.01% | 992 |
|
|
2024
Q2 | $6.56K | Hold |
27
| – | – | ﹤0.01% | 1008 |
|
|
2024
Q1 | $4.04K | Sell |
27
-375
| -93% | -$56K | ﹤0.01% | 1054 |
|
|
2023
Q4 | $76.9K | Sell |
402
-240
| -37% | -$45.9K | ﹤0.01% | 662 |
|
|
2023
Q3 | $114K | Buy |
642
+615
| +2,278% | +$109K | ﹤0.01% | 573 |
|
|
2023
Q2 | $5.13K | Hold |
27
| – | – | ﹤0.01% | 1049 |
|
|
2023
Q1 | $5.41K | Buy |
+27
| New | +$5.41K | ﹤0.01% | 1055 |
|
|
2019
Q4 | – | Sell |
-123
| Closed | -$10K | – | 1110 |
|
|
2019
Q3 | $10K | Hold |
123
| – | – | ﹤0.01% | 884 |
|
|
2019
Q2 | $9K | Buy |
123
+3
| +3% | +$220 | ﹤0.01% | 827 |
|
|
2019
Q1 | $11K | Buy |
+120
| New | +$11K | ﹤0.01% | 821 |
|
|
2018
Q2 | – | Sell |
-15
| Closed | -$2K | – | 810 |
|
|
2018
Q1 | $2K | Sell |
15
-20
| -57% | -$2.67K | ﹤0.01% | 742 |
|
|
2017
Q4 | $4K | Buy |
+35
| New | +$4K | ﹤0.01% | 872 |
|
|
2015
Q2 | – | Sell |
-40
| Closed | -$4K | – | 742 |
|
|
2015
Q1 | $4K | Hold |
40
| – | – | ﹤0.01% | 702 |
|
|
2014
Q4 | $4K | Buy |
+40
| New | +$4K | ﹤0.01% | 763 |
|